Key Points
- Major shareholder Bioventures 2018 L.P. Mpm sold 192,500 Entrada Therapeutics shares at an average price of $7.41, generating $1.43 million. The sale reduced its ownership by 4.69%, leaving it with 3.91 million shares valued at approximately $29.0 million.
- The shareholder also reported eight additional sales between August 27 and September 9, selling shares at prices ranging from $6.99 to $7.20.
- Entrada Therapeutics shares opened at $7.11, near the 50-day average of $7.05 but below the 200-day average of $9.09. The company recently missed quarterly EPS and revenue estimates, while analysts maintain a “Moderate Buy” consensus with an average price target of $17.75.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the sale, the insider owned 3,885,115 shares in the company, valued at approximately $27,700,869.95. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Bioventures 2018 L.P. Mpm also recently made the following trade(s):
- On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00.
- On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.11, for a total transaction of $273,735.00.
- On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total transaction of $231,325.71.
- On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total transaction of $180,691.89.
- On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $205,361.28.
- On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
- On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
- On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.
Entrada Therapeutics Price Performance
Shares of TRDA opened at $7.11 on Thursday. The company has a 50-day simple moving average of $7.05 and a two-hundred day simple moving average of $9.09. The firm has a market capitalization of $276.86 million, a PE ratio of -1.80 and a beta of -0.25. Entrada Therapeutics, Inc. has a one year low of $5.02 and a one year high of $16.45.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million for the quarter, compared to analysts' expectations of $2.32 million. Analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.
Institutional Trading of Entrada Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP grew its stake in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock worth $52,148,000 after buying an additional 206,911 shares during the last quarter. 5AM Venture Management LLC purchased a new position in Entrada Therapeutics during the second quarter valued at $29,854,949. BlackRock Inc. purchased a new position in Entrada Therapeutics during the second quarter valued at $19,013,000. Wellington Management Group LLP raised its stake in Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company's stock valued at $10,740,000 after buying an additional 90,339 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company's stock worth $4,852,000 after acquiring an additional 666,287 shares in the last quarter. 86.39% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on TRDA. Weiss Ratings raised Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 31st. Roth Capital reissued a "buy" rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 5th. Finally, Guggenheim reduced their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating on the stock in a research report on Monday, June 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.75.
Check Out Our Latest Analysis on TRDA
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
